TNFRSF1A and uveitis: Adalimumab (a fully humanized monoclonal antibody that blocks the interaction between TNF-α and TNF R1 and TNF R2 receptor) and infliximab (a chimeric monoclonal antibody directed against TNF-α) were mostly studied in uveitis treatment [20].